REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov) - Aug 29, 2024 - P2/3 | N=600 | Recruiting | Sponsor: Sutro Biopharma, Inc. | Trial completion date: Feb 2026 ➔ Feb 2028 | Trial primary completion date: Sep 2025 ➔ Aug 2027
Trial completion date • Trial primary completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • FOLR1
|